Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Highlights •This study shows that apoA-I may be an alternative strategy to improve the biocompatibility of stents. •Systemic infusions of apoA-I reduce in-stent neointimal hyperplasia in a murine model of stenting. •The cellular phenotype of the neointima post-stenting is altered by apoA-I infusions such that the smooth muscle cell phenotype is preserved, and there are fewer macrophages. •There was an increase in endothelial cell content of the arteries post-stenting in the mice infused with apoA-I, indicating an enhancement of endothelialization. •Systemic infusions of apoA-I inhibit platelet activation.